TargetMol

SCH900776

Product Code:
 
TAR-T2517
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T2517-1mg1mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-2mg2mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-5mg5mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-1mL1 mL * 10 mM (in DMSO)£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-10mg10mg£208.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-50mg50mg£461.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T2517-100mg100mg£629.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CHK1 Inhibitor MK-8776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
CAS:
891494-63-6
Formula:
C15H18BrN7
Molecular Weight:
376.25
Pathway:
Cell Cycle/Checkpoint
Purity:
0.996
SMILES:
Cn1cc(cn1)c1c2nc(c(c(n2nc1)N)Br)[C@@H]1CCCNC1
Target:
Chk; CDK

References

1. Guzi TJ, et al. Mol Cancer Ther, 2011, 10(4), 591-602. 2. Montano R, et al. Mol Cancer Ther, 2012, 11(2), 427-438. 3. Schenk EL, et al. Clin Cancer Res, 2012, 18(19), 5364-5373. 4. Ou J, Li H, Qiu P, et al. CDK9 modulates circadian clock by attenuating REV-ERB? activity[J]. Biochemical and biophysical research communications. 2019 Jun 11;513(4):967-973.